SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2019 financial results and provide a corporate update on Wednesday, February 26, 2020 , after the close of the U.S. financial markets.
- New biomarker data from the open-label extension (OLE) of the Phase 2 OASIS trial for etrasimod in patients with moderately to severely active ulcerative colitis (UC) - Arena sponsored dinner symposium: HYPE, HOPE or REALITY? Integrating histology into a treat-to-target strategy in UC, with
- APD418 currently in Phase 1 clinical investigation - data expected this year SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation for APD418, a β 3 -adrenergic
SAN DIEGO , Jan. 13, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D.
SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 , at 1:00 PM
- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA) - First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF) - Expanded multi-program collaboration
- Selected targets (Project Cabrillo) represent new therapeutic potential across a broad range of immune and inflammatory diseases - Leveraging Beacon's world-class G protein-coupled receptor (GPCR) discovery platform to augment Arena's robust pipeline SAN DIEGO , Jan.
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: Evercore ISI HealthCONx Conference – Presenting on Tuesday, December 3 , at 11:00 AM ET in Boston
- Arena received the 2019 Deal of the Year Award for its global licensing agreement with United Therapeutics for ralinepag, a prostacyclin receptor agonist, in development for the treatment of pulmonary arterial hypertension (PAH) SAN DIEGO , Nov. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals,
- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc.